Robbyant's embodied AI challenge draws over 1,800 teams to Shanghai
More than 1,800 teams from 13 countries have entered a contest built on Robbyant's open-source LingBot-VLA 2.0 model…
Research
Peer-reviewed work, and what it means outside the lab.
69 stories Page 1 of 6
Kelun-Biotech reports Phase III results for sac-TMT in first-line NSCLC
Kelun-Biotech said its TROP2 antibody-drug conjugate combined with pembrolizumab met the primary endpoint of…
Wenda Pharma reports Phase II data for oral BET inhibitor in NUT carcinoma
Zhejiang Wenda Pharmaceutical Technology will publish Phase II results for NHWD-870 HCl in Chinese patients with…
Bio-Thera reports 61.2% response rate for BAT8008 with BAT1308 in first-line NSCLC
Bio-Thera Solutions presented Phase 2 data at ESMO 2026 for its TROP2-targeted antibody-drug conjugate combined with an…
Lunit and Summit Therapeutics to test AI pathology in ivonescimab research
A research agreement will apply Lunit SCOPE IO to H&E whole-slide images to study tumor microenvironment features in…
Ractigen publishes peer-reviewed study of its LiCO extrahepatic RNA delivery platform
The paper reports months-long silencing in muscle, heart and fat in animals, local delivery to joint, eye and bladder…
Full-Life reports Phase 1 PSA declines for FL-020 in mCRPC
Full-Life Technologies presented preliminary dose-escalation data for its PSMA-targeted alpha radiopharmaceutical at…
Rakuten Medical reports 44.3-month median response duration in head and neck cancer follow-up
Long-term data from a 19-patient Phase 1b/2 study of ASP-1929 photoimmunotherapy with pembrolizumab were presented at…
Hengrui Pharma lines up 64 findings for ESMO 2026
The Chinese drugmaker will present three Proffered Papers and three Rapid Orals in Madrid, including phase 3 data on…
Gairdner Science Week 2026 brings laureates to Toronto for free public lectures
The Gairdner Foundation's five-day programme, held in Toronto and streamed online, centres on the 2026 Canada Gairdner…
XellSmart presents Phase I data for off-the-shelf Parkinson's cell therapy
Nine participants in a dose-escalation study showed motor improvements, and a 30-patient Phase II trial in China has…
FDA Clears Phase 2 Study of T-MAXIMUM's MT027 in Brain Metastases
The company said the allogeneic CAR-T therapy will be tested in patients whose cancer has spread to the brain from lung…